Intercell's Japanese Encephalitis vaccine safe in Phase III trials
16-Jan-2006 -
Intercell AG announced the achievement of an important milestone in the progress of its international, multi-center Phase III clinical trial program of its Japanese Encephalitis vaccine. An independent Data and Safety Monitoring Board (DSMB), consisting of two European and one US expert from the ...
clinical trials
immunogenicity
Intercell
+3